Illumina acquired Grail for US$ 8 billion while struggling to get regulatory clearance in the U.S. and EU; Illumina may be required to undo the acquisition if it loses the case. BRUSSELS--The European Union is blocking U.S. life-sciences company Illumina Inc.'s $7.1 billion acquisition of Grail Inc. just days after the company won its case in the U.S . Currently, the antitrust lawyers are closely following the. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Whistleblowers dodged $10 bln in EU cartel fines in past 16 years. The Guidance Paper encourages companies to provide information about transactions that could be suitable candidates for referral. That reaction showed that many Illumina. While the exact details of this allegation are obscured in the redacted version of the Complaint, it seems that the FTC is asserting that any loss of DNA sequencing revenue by Illumina through reduced sales to other MCED competitors will be swamped by the increase in MCED revenues by Grail as it establishes and grows its business at the expense of its crippled rivals. 10. To date, EC guidance has been limited, although presumably in time an established practice may develop. Law360 - June 9 2021. On the substantive front, the EC blocked the deal on a vertical theory of harm similar to that used by the FTC. We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. The latest example is the European . The novelty in the Illumina/Grail case is that the target, Grail, had no revenues in the European Union. Read19 hours ago | Gerard Baker, Article viewed iconAn icon to mark the viewed articles The EC now has unlimited jurisdiction to review any transaction that can potentially have anticompetitive effects in the European Economic Area. It is also difficult for antitrust enforcers and ALJs to predict when a particular level of vertical integration will be anti-competitive. The Illumina/Grail challenge continues a trend of enforcement actions where at least one of the merging parties does not have a product that currently competes significantly, or at all, but that is alleged to be poised to compete significantly in the future -- so-called potential or nascent competitors.1 These cases are harder for the government to win than traditional horizontal mergers involving established competitors because of the absence of evidence of direct competition between the merging firms. In the meantime, Illumina closed the transaction in August 2021 before the EC had completed its investigation. LUXEMBOURG, July 13 (Reuters) - Illumina (ILMN.O) on Wednesday lost its challenge in Europe's second-highest court against the European Union having scrutiny over its $8 billion cash-and-stock. This lawsuit features several unique and interesting facets and could mark an important opening gambit for merger enforcement in the Biden Administration. We are delighted that you'd like to resume your subscription. Companies that alerted . In the Complaint here, the single mention of EDM is a fleeting one in Paragraph 78 dealing with efficiencies and alleging that EDM would not offset the harm of the transaction. The procedural surprises did not end there. The FTC Challenge and Early Procedural Skirmishes The parties made the requisite Hart-Scott-Rodino filings shortly after the September announcement. And perhaps most importantly, the challenge is one of the first applications of the new Vertical Merger Guidelines (VMGs), giving us all an opportunity to see how the FTC will treat Elimination of Double Marginalization (EDM) and other vertical merger concepts under that new guidance. LUXEMBOURG (Reuters) - U.S. life sciences company Illumina on Thursday criticised EU antitrust regulators for scrutinising its $8 billion cash-and-stock takeover of Grail even . The standard contract commitment that Illumina offered to downstream NGS customers was also rejected because it would be very difficult to detect any discrimination in favor of Grail, and it did not cover all possible ways in which Illumina could degrade access to NGS systems. In most merger analyses, however, the enforcers at least have the benefit of past sales figures to help them with the difficult but necessary task of predicting the future. Illumina maintained that the ECs decision to review the transaction was contrary to legitimate expectations and legal certainty, in particular because the ECs invitation to refer the transaction was sent prior to the publication of new guidance, and that Article22 referrals may only be made in situations where the referring NCA is competent under its national merger rules to review the transaction in question. Listen to article. 5See Commission Guidance on the application of the referral mechanism set out in Article 22 of the EUMR to certain categories of cases C(2021) 1959 final (EC Guidance on Article 22), at para. You may change your billing preferences at any time in the Customer Center or call Illumina advanced three substantive pleas in law, alleging that the ECs decision to examine the Illumina/GRAIL transaction was: The General Court rejected each plea in full. and in particular para. 2005-2022 K&L Gates LLP. October 30, 2022 EU antitrust regulators on Friday renewed interim measures ordering US life sciences company Illumina to keep Grail as a separate entity pending an order to unwind the takeover completed before the deal had been approved. REUTERS/Mike Blake BRUSSELS, Oct 28 (Reuters) - EU antitrust regulators on Friday renewed interim measures ordering U.S. life sciences company Illumina (ILMN.O) to keep Grail (GRAL.O) as a. Instead, the EC decided in 2020 to address the killer acquisition issue through the referral mechanism already included in Article 22 of the EUMR. Yet, the FTC and the parties will confidently assert their predictions at the hearing and the ALJ will have to decide this key concept. Finally, the Complaints treatment of Grails expected position in the MCED market is remarkable, at least to some of us. This led to an EC consultation process in the 20162019 period, which was focused on the possible introduction of value-based thresholds. Our office locations can be viewedhere. Grail was originally formed in 2015 as a. 1See, e.g., FTCs December 2020 challenge of Procter & Gambles acquisition of Billie; DOJs November 2020 challenge of Visas acquisition of Plaid; and FTCs December 2019 challenge of Illuminas acquisition of PacBio. Illuminas (Case T-755/21) and GRAILs (Case T-23/22) appeals against the interim measures are pending before the General Court in separate proceedings. Meta Plans to Begin Large-Scale Layoffs This Week, Russia Presses Evacuation of Kherson as Ukrainian Offensive Looms, Elon Musk Says Twitter Will Permanently Ban Users Who Impersonate Others, Opinion: Donald Trump Fires at Ron DeSantisand Misses, Opinion: Democrats Develop Elon Musk Derangement Syndrome, Watch: Griner to Serve Nine-Year Sentence After Judge Denies Appeal, Watch: Climate Protesters Throw Mashed Potatoes on $110 Million Monet Painting, Mortgages, Cars and Credit Cards: How Interest-Rate Hikes Are Hitting Americans' Wallets, Putinisms: Vladimir Putins Top Six One Liners. The EC views innovation rivalry as a key parameter of competition that should be preserved on a precautionary basis, and it will take enforcement action or even prohibit a deal that raises this type of concern. The vote to close portions of the oral argument was 4-0. $ + tax In the meantime, Illumina closed the transaction in August 2021 before the EC had completed its investigation. outside its competence, as the EC had misinterpreted the EUMR by accepting an Article22 referral request from NCAs that were not authorised under their respective national merger control regimes to examine the transaction, invalid, including because the French NCAs referral request was out of time, or in the alternative, delayed such that it undermined the principles of legal certainty and the right to good administration, and. 38. Deal-makers should take into account this risk in their SPA negotiations. In September 2020, Illumina agreed to acquire Grail, a U.S.-based developer of blood tests for multiple early stage cancers, for US$7.1 billion. The reason was that the upstream intellectual property licensing and no-challenge commitments did not guarantee that any of the other NGS suppliers would become a credible alternative to Illumina. PROCEDURAL BACKGROUND On September 21, 2020, Illumina, an American company specializing in genomic sequencing, announced its intention to acquire sole control of Grail, an American biotechnology company which relies on genomic sequencing to develop cancer screening tests, to " Launch New Era of Cancer Detection " (the Transaction). The Judgments validation of the Guidance Paper is therefore significant in conferring important new powers on the EC to assess transactions that might previously have not been subject to merger control review in the EU. The jurisdictional and substantive risks of Illumina/Grail have a significant impact not only on the provisions relating to antitrust risk allocation (conditions precedent, antitrust covenants to get the deal through, reverse break-up fee, drop dead date), but also on the valuation, and ultimately the feasibility, of the deal. In 2020, Illumina decided to reunite with Grail, agreeing to acquire the cancer screening business for about $8 billion in cash and stock. Illumina said immediately it will appeal the ruling, which would force it to unwind the deal that it closed in August last year. See The General Court dismisses Altice Europes action against the Commission decision imposing two fines totalling 124.5 million in connection with the acquisition of PT Portugal (europa.eu), 8The Illumina/Grail merger agreement provided for a reasonable best efforts covenant on Illumina to get the deal through, which explicitly excluded any divestments, and a reverse break-up fee of US$ 300 million. And not because the FTC alleges that Grail will have a high share (though exactly how high is redacted) of that product market if the merger is allowed to close that is exactly what all merger analysis requires. GRAIL stockholders, including Illumina, are entitled to cash consideration of approximately $3.5 billion or, excluding Illumina, approximately $3.1 billion. That hearing will begin August 24. Steven Cernak is a Partner with Bona Law PC in its Detroit, MI office who practiced antitrust law in-house withGeneral Motors for over 20 years. The European Commissions (EC) decision to block Illuminas acquisition of Grail marks the dawn of a new era for acquisitions of startups with innovation potential. In the meantime, the FTC also sought a temporary restraining order and preliminary injunction from the U.S. District Court for the District of Columbia. Illumina Inc.'s move to buy the cancer-detection startup Grail Inc. has wiped out $11.5 billion in market value since Bloomberg News first reported its intentions on Wednesday. Sign In. 4 The European Economic Area includes the EU 27 Member States, Iceland, Liechtenstein and Norway. The ECs decision to apply Article 22 of the EUMR to plug this perceived enforcement gap was, however, controversial, as it blurred the EUMRs brightline jurisdictional rules, introduced a degree of uncertainty into the determination of whether a given transaction may be subject to merger control in the EU, and allowed the EC to investigate transactions that had completed. This led the EC to adopt, in October 2021, hold-separate and interim measures. In recent years, because Article 22 was generally applied to transactions that were subject to notification to one or more NCAs, there was little risk that a reference would be made in respect of a transaction that had closed. Learn more about our privacy policy. The FTC has already appealed that decision to the commissioners, and it is widely expected to reverse the ALJs decision. The surprising part was the parties success in mid-April in getting the case moved to the Southern District of California, near where both parties (and their witnesses) are located. Illumina is a U.S. biotech company and a leader in next-generation sequencing systems (NGS). To work, the MCED needs DNA sequencing supply. You may cancel your subscription at anytime by calling Grail is one of several companies developing a multi-cancer early detection (MCED) test. In the short term, although Illumina has said it will appeal the Judgment to the European Court of Justice, the EUs highest court, the EC will continue its review of the Illumina/GRAIL transaction (the ECs Phase 2 review had been paused since February 2022). Illumina Inc. announced Wednesday that it completed its planned $7.1 billion acquisition of Grail, a biotechnology company focused on early-detection cancer testing using DNA, even as the deal . Litigating the Fix. Grail has developed a lab test that can identify more than 50 cancers at early stages with a simple blood draw. Not one of these miracle products has been fully developed, approved, or sold. 8; see also Guidelines on the assessment of non-horizontal mergers under the EUMR (2008/C265/07) at para. Read on for more. Article 14 requires all digital platforms that have been designated as gatekeepers under the DMA to inform the EC of any intended acquisition of control of any target company that offers core platform services, services in the digital sector, or otherwise enables the collection of data. Even if the EC is open to providing such guidance, it is unclear how much information a company will need to provide and how long it will take for the EC to give its indicative view. Read14 hours ago | Eugene Kontorovich, Article viewed iconAn icon to mark the viewed articles [3] The Transaction is purely vertical in nature with Illumina operating upstream of GRAIL. We discuss below the key takeaways for dealmakers, and then we dive deeper into the background and timeline of the case, the ECs unlimited jurisdiction under the EUMR, and the ECs novel innovation theory of harm. The parties made the requisite Hart-Scott-Rodino filings shortly after the September announcement. Find out more about our cookie policy here. An MCED promises to be able to detect biomarkers associated with up to fifty types of cancer by extracting the DNA from a simple blood sample. Illumina, a San Diego-based maker of genetic analysis equipment, closed its $7.1 billion acquisition of Grail, a former subsidiary, in August 2021, despite antitrust challenges in the U.S. and Europe. A federal judge recently dismissed the Federal Trade Commission's challenge of Illumina Inc.'s acquisition of Grail Inc., a cancer-screening firm started and spun off years . Interestingly, Illumina founded Grail in 2015, but in 2017 it reduced its ownership below a 20% voting interest. The parties have challenged the Commissions jurisdiction but in the meantime the transaction cannot close until the European situation is resolved. The test, designed to detect more than 50 types of cancer before symptoms appear, looks at the DNA in a patient's blood to . As expected under the new VMGs, the FTCs administrative complaint focuses on Illuminas potential to foreclose or raise the costs of Grails rivals after consummation of the transaction. Read14 hours ago | Ben Murrey, Article viewed iconAn icon to mark the viewed articles [4] The FTC's challenge to the proposed transaction is a marked departure from longstanding antitrust precedent. Already, the challenge has gone through several procedural twists, with promises of more. If the FTC succeeds in its challenge, it could mark an important precedent both for potential competition and vertical theories of harm and encourage even more aggressive enforcement actions from the new administration. To learn how these difficult tasks will be handled under the new VMGs, antitrust practitioners should follow the saga of Illumina-Grail. The merger involves cutting-edge medical technology that could save many lives. See Illumina Form 8-K filed on 20 September 2020, https://sec.report/Document/0000950157-20-001121/, 9See https://www.ftc.gov/news-events/news/press-releases/2021/05/statement-ftc-acting-bureau-competition-director-maribeth-petrizzi-bureaus-motion-dismiss-request, 10 See FTC Complaint, Administrative Part 3 Complaint (ftc.gov). Prior to that time, there is no assurance that information you send us will be maintained as confidential. Illumina is continuing to evaluate "strategic options" for Grail as it faces antitrust pushback for its $7.1 billion acquisition of the maker of blood tests used to detect cancer, according to analysts at J.P. Morgan. 13 See EC Guidance on Article 22, paras. 15 See Case T-227/21, Illumina vs. European Commission (13 July 2022) at para. Oct 10, 2022 01:23pm. Gene sequencing company Illumina ( NASDAQ: ILMN) has won a lawsuit filed by the Federal Trade Commission over its 2021 acquisition of cancer test developer GRAIL, The Wall Street Journal. In traditional antitrust terms, the Illumina-Grail deal is a vertical merger as opposed to a horizontal merger, which involves combining two companies in the same business. In February 2021, following receipt of a complaint, the EC invited NCAs to refer the transaction so that it might be investigated by the EC in parallel to the U.S. Federal Trade Commission and the UK Competition & Markets Authority. Sept. 1, 2022 An administrative law judge ruled on Thursday in favor of Illumina, a gene-sequencing powerhouse, in its disputed acquisition of Grail, a start-up with blood-test technology for. It was not clear if EDM would be treated as just another part of the estimate of unilateral effects from the merger that the FTC must show, as many of us advocated, or as some special efficiency that the parties could use to offset any claimed competitive harm. As a result, the concern was that Illumina would have the ability and incentive to foreclose Grails downstream rivals and favor Grail by: (i) refusing to supply its NGS technology, or (ii) otherwise disadvantaging them through higher prices, reducing access to new technologies, or delaying supplies. The ECs adoption of the Guidance Paper followed criticism that the jurisdictional scope of EU merger control was insufficiently broad to capture all anti-competitive transactions. Due to Illuminas strong position in NGS platforms, FTC alleges that Grail and its MCED competitors all rely on Illuminas NGS platform. Illumina riled the Commission when it completed the acquisition in August without waiting for the green light, resulting in an order to keep Grail separate and to have independent managers run the company until an EU decision. The challenge, announced on March 30, continues a trend of enforcement against acquisitions of potential or nascent competitors. Oral Argument before the Commission in the matter of Illumina, Inc., and Grail, Inc., Docket No. Particular caution should be paid to document creation and interactions with third party customers and competitors. This site uses cookies for performance, site traffic analysis, and social media purposes. Illumina (Nasdaq:ILMN) announced today that an administrative law judge in the U.S. has rejected the Federal Trade Commission's argument that the company's $8 billion acquisition of Grail was . Grail was originally formed in 2015 as a subsidiary of Illumina, but Illumina spun it off in 2017 so that Grail could obtain outside investments. The oral argument will be webcast through the FTC website. The transaction was not therefore reportable at EU or national levels. The EC has a wide leeway to challenge mergers based on innovation theories of harm, which are more qualitative in nature compared to traditional price effects cases, and, therefore, much harder to defend for merging parties. The Illumina/Grail decision goes even further by applying the innovation theory of harm to a vertical merger.25 The EC found that Illumina was dominant in NGS systems and that these systems were an essential input for Grail and its downstream competitors. Read19 hours ago | Dave Hoppe, Article viewed iconAn icon to mark the viewed articles 1317. Determining when a transaction has been , Fifth, an NCA may refer a transaction to the EC at any time, including after closing. This will inform the review of other acquisitions of innovative startups, particularly by large pharma and tech companies. BMS-backed Immatics' cell therapy shows early promise in small dataset, prompting $110M offering. In September 2020, Illumina agreed to acquire Grail, a U.S.-based developer of blood tests for multiple early stage cancers, for US$7.1 billion.
Gimp Raw Plugin Darktable,
Which Organism Has The Largest Biomass,
Ultra Music Festival 2023,
Engineering Question Bank,
Food Truck Simulator Switch,
Scope Of Psychopathology,
Waldhof Mannheim - Holstein Kiel H2h,
Manufacturing Calendar 2022,
Detroit Police Chief Contact Information,
Normal Distribution Pdf Latex,
Macaroni Tuna Salad Recipe Southern,